Jagsonpal Pharmaceutical Shares in Focus: Board to Consider Share Buyback

On Tuesday, March 10, 2026, Jagsonpal Pharmaceutical shares are in focus, after the company announced that its board will consider a proposal for a share buyback.

In a filing with the stock exchanges on Monday, the company said its board of directors is scheduled to meet on Thursday, March 12, 2026, to consider and potentially approve the buyback of fully paid-up equity shares with a face value of ₹2 each.

Corporate Action History

According to data from the Bombay Stock Exchange (BSE), this will mark the company’s first share buyback if the proposal receives board approval.

Jagsonpal Pharmaceutical has previously undertaken other corporate actions. In July 2004, the company issued bonus shares in a 3:1 ratio, granting shareholders three additional shares for every one share held on the record date.

More recently, in January 2025, the company implemented a stock split, reducing the face value of its shares from ₹5 to ₹2.

The company has also maintained a record of dividend payouts. It declared a final dividend of ₹2.5 per share in September 2025. Prior to that, it paid dividends of ₹5 each in September 2024 and August 2023. In 2021, the company announced two dividends of ₹4 and ₹1 in October and September, respectively.

Management Take on Q3FY26 Earnings

Commenting on the performance, Manish Gupta, Managing Director and CEO, Jagsonpal Pharmaceuticals Limited said, “We have reported stable performance during the nine months of FY26, even as we took focused initiatives to support growth. These should start reflecting in our performance from the ongoing quarter. Revenue increased 6% YoY to ₹2,230 Mn, while EBITDA (pre-ESOP) grew 5% YoY to ₹503 Mn. 

Also Read: March 31, 2026, Deadline: Ensure NPS, PPF, SSY Deposits to Keep Accounts Active

Operational PAT rose 12.5% YoY to ₹359 Mn, with Operating PAT margins expanding by 95 bps to 16.1%, underscoring the strength of our brands and our business model. On a quarterly basis, performance was largely flat, with revenue at ₹729 Mn, EBITDA (pre-ESOP) of ₹166 Mn, with Operational PAT increasing 10% to ₹125 Mn. Based on initial estimations, we have provided for an additional past service cost of ₹ 21 Mn.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks. Read all related documents carefully before investing.